$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000106282214000022 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$676.0K	$277.0K	$360.0K
YoY Change	215.89%	-23.06%	20.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.000M	$5.300M	$4.300M
YoY Change	6.38%	23.26%	-23.21%
% of Gross Profit
Research & Development	$21.19M	$23.95M	$20.33M
YoY Change	-10.57%	17.84%	-11.76%
% of Gross Profit
Depreciation & Amortization	$600.0K	$644.0K	$793.0K
YoY Change	-25.0%	-18.79%	-29.51%
% of Gross Profit
Operating Expenses	$26.79M	$30.75M	$25.92M
YoY Change	-7.11%	18.65%	-12.69%
Operating Profit	-$26.11M	-$30.47M	-$25.56M
YoY Change	-8.78%	19.24%	-13.03%
Interest Expense	$455.0K	$457.0K	$506.0K
YoY Change	-8.27%	-9.68%	-5.77%
% of Operating Profit
Other Income/Expense, Net	$538.0K	$94.00K	$34.00K
YoY Change	-13550.0%	176.47%	-950.0%
Pretax Income	-$26.00M	-$30.80M	-$26.00M
YoY Change	-10.65%	18.46%	-13.04%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$26.03M	-$30.84M	-$25.97M
YoY Change	-10.5%	18.71%	-13.04%
Net Earnings / Revenue	-3850.3%	-11131.77%	-7215.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$353.7K	-$419.6K	-$355.2K
COMMON SHARES
Basic Shares Outstanding	514.9M shares	513.8M shares	513.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.60M	$97.90M	$196.7M
YoY Change	-55.06%	-50.23%	-22.31%
Cash & Equivalents	$27.73M	$46.52M	$34.25M
Short-Term Investments	$50.90M	$51.40M	$162.5M
Other Short-Term Assets	$7.342M	$6.570M	$8.438M
YoY Change	9.84%	-22.14%	64.07%
Inventory
Prepaid Expenses
Receivables	$281.0K	$471.0K	$863.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$86.67M	$105.4M	$206.5M
YoY Change	-52.66%	-48.95%	-20.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.18M	$39.96M	$42.62M
YoY Change	-7.06%	-6.25%	-6.38%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.56M	$53.56M	$53.56M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$120.0K	$133.0K	$88.00K
YoY Change	84.62%	51.14%	-51.38%
Total Long-Term Assets	$137.4M	$138.2M	$140.8M
YoY Change	-2.08%	-1.86%	-2.08%
TOTAL ASSETS
Total Short-Term Assets	$86.67M	$105.4M	$206.5M
Total Long-Term Assets	$137.4M	$138.2M	$140.8M
Total Assets	$224.1M	$243.6M	$347.3M
YoY Change	-30.71%	-29.85%	-13.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.350M	$7.072M	$5.442M
YoY Change	32.94%	29.95%	2.22%
Accrued Expenses	$10.89M	$7.952M	$9.704M
YoY Change	-3.84%	-18.05%	-29.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.783M	$1.746M	$1.607M
YoY Change	-92.14%	8.65%	8.73%
Total Short-Term Liabilities	$21.90M	$17.67M	$17.38M
YoY Change	-46.47%	1.68%	-16.97%
LONG-TERM LIABILITIES
Long-Term Debt	$19.26M	$19.71M	$21.46M
YoY Change		-8.14%	-6.96%
Other Long-Term Liabilities	$34.82M	$34.02M	$34.08M
YoY Change	-1.23%	-0.18%	-40.39%
Total Long-Term Liabilities	$54.08M	$53.73M	$55.54M
YoY Change	53.38%	-3.26%	-30.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.90M	$17.67M	$17.38M
Total Long-Term Liabilities	$54.08M	$53.73M	$55.54M
Total Liabilities	$107.4M	$102.8M	$105.1M
YoY Change	-0.84%	-2.13%	-21.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.061B	-$1.035B	-$925.8M
YoY Change	11.09%	11.77%	12.97%
Common Stock	$516.0K	$516.0K	$514.0K
YoY Change	0.39%	0.39%	6.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.390M	$2.390M	$1.503M
YoY Change	59.02%	59.02%	138.57%
Treasury Stock Shares	1.281M shares	1.281M shares	814.0K shares
Shareholders Equity	$116.7M	$140.8M	$242.2M
YoY Change
Total Liabilities & Shareholders Equity	$224.1M	$243.6M	$347.3M
YoY Change	-30.71%	-29.85%	-13.78%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$26.03M	-$30.84M	-$25.97M
YoY Change	-10.5%	18.71%	-13.04%
Depreciation, Depletion And Amortization	$600.0K	$644.0K	$793.0K
YoY Change	-25.0%	-18.79%	-29.51%
Cash From Operating Activities	-$19.70M	-$30.32M	-$24.27M
YoY Change	-6.64%	24.92%	-10.11%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$28.00K	$839.0K
YoY Change	-100.0%	-96.66%	258.55%
Acquisitions
YoY Change
Other Investing Activities	$1.200M	$40.60M	$29.90M
YoY Change	-88.99%	35.79%	-123.12%
Cash From Investing Activities	$1.200M	$40.57M	$29.11M
YoY Change	-88.46%	39.38%	-122.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$811.0K	$624.0K
YoY Change		29.97%	167.81%
Debt Paid & Issued, Net		$420.0K	$387.0K
YoY Change		8.53%	9.63%
Cash From Financing Activities	-400.0K	-$1.231M	-$1.011M
YoY Change	33.33%	21.76%	40.03%
NET CHANGE
Cash From Operating Activities	-19.70M	-$30.32M	-$24.27M
Cash From Investing Activities	1.200M	$40.57M	$29.11M
Cash From Financing Activities	-400.0K	-$1.231M	-$1.011M
Net Change In Cash	-18.90M	$9.018M	$3.825M
YoY Change	71.82%	135.76%	-102.43%
FREE CASH FLOW
Cash From Operating Activities	-$19.70M	-$30.32M	-$24.27M
Capital Expenditures	$0.00	$28.00K	$839.0K
Free Cash Flow	-$19.70M	-$30.35M	-$25.11M
YoY Change	-4.83%	20.86%	-7.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9715000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7072000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	790000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	471000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7674000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7952000	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80747000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81945000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1177432000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1175108000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2109000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2250000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2100000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2300000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2014Q1	us-gaap	Assets Assets	243600000	USD
CY2013Q4	us-gaap	Assets Assets	274160000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	134554000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	105408000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37499000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46517000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30423000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34248000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3825000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9018000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	516000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30827000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25955000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	172000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	284000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	903000	USD
CY2014Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13405000	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12679000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	644000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	793000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1264000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1142000	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31184000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	29920000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28852000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	27710000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	264000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5654000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4324000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	44543000	USD
CY2014Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4100000	USD
CY2014Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	242000	USD
CY2013Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1876000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	905000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-515000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-319000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	18000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	11000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	21000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2089000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1934000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53557000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	457000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	506000	USD
CY2013Q1	us-gaap	Interest Paid Net InterestPaidNet	480000	USD
CY2014Q1	us-gaap	Interest Paid Net InterestPaidNet	447000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	53000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	103997000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	102825000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	274160000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243600000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19294000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17673000	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	105000	USD
CY2013Q1	us-gaap	Licenses Revenue LicensesRevenue	76000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1710000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1746000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20167000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19711000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1011000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1231000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40568000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29107000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30319000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24271000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-25974000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-30835000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	25915000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	420000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	30749000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25555000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30472000	USD
CY2014Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6570000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4636000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	144000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	133000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32386000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34017000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	86000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	887000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	873000	USD
CY2014Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20651000	USD
CY2013Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	80954000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	839000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	76000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249000	USD
CY2014Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60438000	USD
CY2013Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	110843000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	57000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	809000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39959000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41362000	USD
CY2013Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2014Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	91629000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	387000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23953000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20327000	USD
CY2013Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q1	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2014Q1	us-gaap	Restructuring And Related Cost Cost Incurred To Date RestructuringAndRelatedCostCostIncurredToDate	4000000	USD
CY2014Q1	us-gaap	Restructuring Reserve RestructuringReserve	1100000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1034793000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1003958000	USD
CY2013Q1	us-gaap	Revenues Revenues	360000	USD
CY2014Q1	us-gaap	Revenues Revenues	277000	USD
CY2014Q1	us-gaap	Secured Debt SecuredDebt	21500000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2250000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2109000	USD
CY2014Q1	us-gaap	Short Term Investments ShortTermInvestments	51850000	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	19000	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	8000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	76000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	140775000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	170163000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	170163000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140775000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	242208000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	266678000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	814000	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1281000	shares
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2390000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1503000	USD
CY2014Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	887000	USD
CY2013Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	873000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	512428000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	513955000	shares
CY2013Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1264000	USD
CY2014Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1142000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	7650622	shares
CY2014Q1	lxrx	Restructuring Cost Other Costs High Endof Range RestructuringCostOtherCostsHighEndofRange	1000000	USD
CY2014Q1	lxrx	Restructuring Cost Other Costs Low Endof Range RestructuringCostOtherCostsLowEndofRange	500000	USD
CY2014Q1	lxrx	Restructuring Cost Severance Costs RestructuringCostSeveranceCosts	5300000	USD
CY2014Q1	lxrx	Restructuring Cost Total Expected Cost High Endof Range RestructuringCostTotalExpectedCostHighEndofRange	6300000	USD
CY2014Q1	lxrx	Restructuring Cost Total Expected Cost Low Endof Range RestructuringCostTotalExpectedCostLowEndofRange	5800000	USD
CY2014Q1	lxrx	Restructuringand Related Costs Cost Incurredto Date Generaland Administrative RestructuringandRelatedCostsCostIncurredtoDateGeneralandAdministrative	400000	USD
CY2014Q1	lxrx	Restructuringand Related Costs Cost Incurredto Date Researchand Development RestructuringandRelatedCostsCostIncurredtoDateResearchandDevelopment	3600000	USD
CY2014Q1	lxrx	Restructuringand Related Costs Cost Incurredto Date Stockbased Compensation RestructuringandRelatedCostsCostIncurredtoDateStockbasedCompensation	100000	USD
CY2014Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	792000	USD
CY2013Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	779000	USD
CY2014Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1458000	USD
CY2013Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1330000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	13237519	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	514942165	shares
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE

Files In Submission

Name	View Source	Status
0001062822-14-000022-index-headers.html	Edgar Link	pending
0001062822-14-000022-index.html	Edgar Link	pending
0001062822-14-000022.txt	Edgar Link	pending
0001062822-14-000022-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20140331.xml	Edgar Link	completed
lxrx-20140331.xsd	Edgar Link	pending
lxrx-20140331_cal.xml	Edgar Link	unprocessable
lxrx-20140331_def.xml	Edgar Link	unprocessable
lxrx-20140331_lab.xml	Edgar Link	unprocessable
lxrx-20140331_pre.xml	Edgar Link	unprocessable
lxrx331201410-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q2 Form 10-Q Financial Statement

#000106282214000022 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2014 Q2 Form 10-Q Financial Statement

#000106282214000022 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx